AI Article Synopsis
Article Abstract
Urothelial carcinoma is usually characterized by severe symptoms including macroscopic haematuria. We here report the case of a female patient without a history of smoking or urothelial carcinoma, making it, to our knowledge, a unique case and a first case of urothelial carcinoma revealed by brain metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046121 | PMC |
| http://dx.doi.org/10.11604/pamj.2019.34.184.15767 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Metastatic involvement of the acromioclavicular joint in a patient with papillary carcinoma of the ureter.
Front Surg
January 2025
Department of Orthopedics, Dokuz Eylul University, Izmir, Türkiye.
Ureteral papillary carcinoma is a rare subtype of urothelial carcinoma, ranking fourth among cancers following prostate (or breast) cancer, lung cancer, and colorectal cancer. Although previous studies have documented bone metastases mainly in the pelvis, spine, ribs, and femur, this case report presents the first recorded instance of metastasis occurring in the acromioclavicular joint. A 62-year-old woman with a history of left flank pain and macroscopic hematuria underwent a left nephroureterectomy, which revealed ureteral papillary carcinoma.
View Article and Find Full Text PDFAntibody-drug conjugates in urothelial carcinoma: current status and future.
Curr Opin Urol
January 2025
Department of Medicine, Division of Hematology and Oncology, New York Presbyterian Weill Cornell Medical Center.
Purpose Of Review: Antibody-drug conjugates (ADCs) are quickly becoming frontline standard of care in many tumor types, including urothelial carcinoma. This review summarizes recent clinical investigations into the use of ADCs targeting nectin-4, trophoblast cell surface antigen-2 (Trop-2), human epidermal growth factor receptor 2 (HER-2), and other antigens in urothelial carcinoma.
Recent Findings: This review covers efficacy and toxicity data of ADCs alone and in combination with immunotherapy; mechanisms of resistance; and preclinical studies that provide biological basis for clinical approaches.
Background And Objective: Intravesical instillation of chemotherapy (IIC) after radical surgery for upper urinary tract urothelial carcinoma (UTUC) reduces the risk of intravesical recurrence (IVR). However, compliance is low because of possible extravesical leakage after bladder cuff excision. The aim of this study was to evaluate the efficacy of preoperative IIC in reducing the risk of IVR.
View Article and Find Full Text PDFReanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.
JAMA Netw Open
January 2025
Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel.
Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!